Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Phase 3 Study Expected to Begin in Q2 2015
DUBLIN, IRELAND--(Healthcare Sales & Marketing Network) - Horizon Pharma plc (HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commerci... Biopharmaceuticals, Neurology, FDAHorizon Pharma, ACTIMMUNE, Friedreich's Ataxia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Actimmune | Ataxia | Brain | Friedreich's Ataxia | Investigational New Drugs | Marketing | Neurology | New Drug Applications | Pharmaceuticals | Study